TransCode Therapeutics, Inc. is a clinical-stage oncology company focusing on metastatic disease treatment through RNA therapeutics using their TTX nanoparticle platform. Their lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a key biomarker. Their preclinical projects include TTX-siPDL1, which modulates PD-L1, TTX-RIGA, an RNA-based RIG-I agonist enhancing innate immunity in tumors, and TTX-CRISPR, a CRISPR/Cas9 therapy for correcting cancer genes. Additionally, they have TTX-mRNA, a platform for creating cancer vaccines specific to tumor types. We show 15 historical shares outstanding datapoints in our coverage of RNAZ's shares outstanding history.
Understanding the changing numbers of RNAZ shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like RNAZ versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching RNAZ by allowing them to research RNAZ shares outstanding history
as well as any other stock in our coverage universe. |
Free RNAZ Email Alerts:
Video: Shares Outstanding Importance
